计算溶液所需的质量、体积或浓度。
| 活性类型 | Relation | Activity value | Units | Action Type | 期刊 | PubMed Id | doi | Assay Aladdin ID |
|---|
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| N129779-100mg |
100mg |
现货 ![]() |
| |
| N129779-500mg |
500mg |
现货 ![]() |
| |
| N129779-1g |
1g |
现货 ![]() |
| |
| N129779-5g |
5g |
现货 ![]() |
| |
| N129779-25g |
25g |
现货 ![]() |
| |
| N129779-100g |
100g |
现货 ![]() |
|
| 别名 | 奈韦拉平 |
|---|---|
| 英文别名 | HMS3655I08 | HMS3715B10 | MLS001424058 | Nevirapine [USAN:USP:INN:BAN] | Nevirapine) | SCHEMBL3318 | NSC 641530 | 11-cyclopropyl-4-methyl-5H-dipyrido[[?],[?]][1,4]diazepin-6-one | NEVIRAPINE [VANDF] | NEVIRAPINE [WHO-DD] | Viramune (TN) | Viramune IR | AC |
| 规格或纯度 | ≥98%(HPLC) |
| 英文名称 | Nevirapine |
| 生化机理 | 奈韦拉平是一种强效(IC50 = 84nM)、选择性的非核苷类 HIV-1 逆转录酶(HIV-1 RT)抑制剂。 |
| 应用 | A potent, non-selective inhibitor of HIV-1 reverse transcriptase. |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 人体免疫缺陷病毒 1 型逆转录酶抑制剂 |
| 产品介绍 |
Nevirapine 是一种非核苷逆转录酶抑制剂(NNRTI),用于治疗HIV-1感染和AIDS。A potent, non-selective inhibitor of HIV-1 reverse transcriptase. Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used to treat HIV-1 infection and AIDS. |
| ALogP | 2 |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 504750768 |
|---|---|
| 分子类型 | 小分子 |
| IUPAC Name | 2-cyclopropyl-7-methyl-2,4,9,15-tetrazatricyclo[9.4.0.03,8]pentadeca-1(11),3,5,7,12,14-hexaen-10-one |
| INCHI | InChI=1S/C15H14N4O/c1-9-6-8-17-14-12(9)18-15(20)11-3-2-7-16-13(11)19(14)10-4-5-10/h2-3,6-8,10H,4-5H2,1H3,(H,18,20) |
| InChi Key | NQDJXKOVJZTUJA-UHFFFAOYSA-N |
| Canonical SMILES | CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4 |
| Isomeric SMILES | CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4 |
| WGK Germany | 2 |
| PubChem CID | 4463 |
| 分子量 | 266.3 |
| 溶解性 | Soluble in Chloroform and Methanol |
|---|---|
| 敏感性 | 对热敏感 |
| 熔点 | 247-249°C |
| 分子量 | 266.300 g/mol |
| XLogP3 | 2.000 |
| 氢键供体数Hydrogen Bond Donor Count | 1 |
| 氢键受体数Hydrogen Bond Acceptor Count | 4 |
| 可旋转键计数Rotatable Bond Count | 1 |
| 精确质量Exact Mass | 266.117 Da |
| 单同位素质量Monoisotopic Mass | 266.117 Da |
| 拓扑极表面积Topological Polar Surface Area | 58.100 Ų |
| 重原子数Heavy Atom Count | 20 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 397.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| Purity(NonaqueousTitration) | 97.5-102.5(%) |
|---|---|
| Purity(HPLC) | 98-100(%) |
| Melting point | 244-248(℃) |
| Appearance(N129779) | White to tan powder |
| Proton NMR spectrum | Conforms to Structure |
| 1. Mingtong Ye, Nengzhi Pang, Ting Wan, Yuanling Huang, Tianyi Wei, Xuye Jiang, Yujia Zhou, Yufeng Huang, Hainan Yang, Zhenfeng Zhang, Lili Yang. (2019) Oxidized Vitamin C (DHA) Overcomes Resistance to EGFR-targeted Therapy of Lung Cancer through Disturbing Energy Homeostasis. Journal of Cancer, 10 (3): ( 757–764). [PMID:30719175] [10.7150/jca.28087] |
| 2. Mingtong Ye, Sufan Wang, Ting Wan, Rui Jiang, Yun Qiu, Lei Pei, Nengzhi Pang, Yuanling Huang, Yufeng Huang, Zhenfeng Zhang, Lili Yang. (2017) Combined Inhibitions of Glycolysis and AKT/autophagy Can Overcome Resistance to EGFR-targeted Therapy of Lung Cancer. Journal of Cancer, 8 (18): ( 3774–3784). [PMID:29151965] [10.7150/jca.21035] |
| 1. Mingtong Ye, Nengzhi Pang, Ting Wan, Yuanling Huang, Tianyi Wei, Xuye Jiang, Yujia Zhou, Yufeng Huang, Hainan Yang, Zhenfeng Zhang, Lili Yang. (2019) Oxidized Vitamin C (DHA) Overcomes Resistance to EGFR-targeted Therapy of Lung Cancer through Disturbing Energy Homeostasis. Journal of Cancer, 10 (3): ( 757–764). [PMID:30719175] [10.7150/jca.28087] |
| 2. Mingtong Ye, Sufan Wang, Ting Wan, Rui Jiang, Yun Qiu, Lei Pei, Nengzhi Pang, Yuanling Huang, Yufeng Huang, Zhenfeng Zhang, Lili Yang. (2017) Combined Inhibitions of Glycolysis and AKT/autophagy Can Overcome Resistance to EGFR-targeted Therapy of Lung Cancer. Journal of Cancer, 8 (18): ( 3774–3784). [PMID:29151965] [10.7150/jca.21035] |